Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial
Randomized study in people · 2012
- What was studied
- CASTA: 1,070 acute ischemic-stroke patients; randomized within 12 hours; 90-day follow-up
- Main finding
- The combined primary outcome showed no significant benefit. A favorable signal in more severe strokes arose in post-hoc analysis.
Reported findings and study design
CASTA: 1,070 patients, randomized within 12 hours; Cerebrolysin 529 versus placebo 541. Intravenous 30 mL/day for ten days plus aspirin 100 mg/day; 90-day follow-up.
Population or model CASTA: 1,070 acute ischemic-stroke patients; randomized within 12 hours; 90-day follow-up
Dose, route and schedule
Cerebrolysin: 30 mL intravenously daily for 10 days, starting within 12 hours of stroke onset. Background treatment included aspirin 100 mg/day; the comparison used placebo.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Combined primary outcome | No significant between-group difference | |
| Severe-stroke subgroup: NIHSS outcome | OR 1.27; lower CI bound 0.97 | Exploratory subgroup with baseline NIHSS>12 |
| Severe-stroke subgroup: mRS outcome | OR 1.27; lower CI bound 0.90 | Exploratory subgroup |
| Severe-stroke subgroup: 90-day mortality | 10.5% Cerebrolysin versus 20.2% placebo | Abstract reports HR 1.9661 and lower CI bound 1.0013; direction follows the source |
Primary result was neutral. Subgroup findings are post hoc; the incomplete confidence intervals are reproduced without inventing upper bounds.
Source for these results ↗ · Reviewed 2026-10-29
Study limitations and source details
Study limitations
- The severe-stroke subgroup is exploratory, not confirmation of efficacy.
- The meta-analyses that include CASTA already account for this trial.
Source details
Indexed citation and abstract reviewed via Europe PMC / PubMed; full methods and risk of bias not comprehensively appraised.
Abstract reviewed
Sources checked
Citation
Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z, Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial Stroke · PMID 22282884
Study source ↗ · DOI 10.1161/strokeaha.111.628537 · Bibliography entry · Link to this summary